124 related articles for article (PubMed ID: 33721440)
1. Cancer stage-dependent alterations in cell-free DNA in patients with colorectal cancer.
Pu W; Xiao L; Zhou C; Zhong F; Wu Y; Gong W; Lv X; Zhuang Z; Wang H; Bian H; Wang J; Zhang R; Li K; Xing C
J BUON; 2021; 26(1):109-115. PubMed ID: 33721440
[TBL] [Abstract][Full Text] [Related]
2. Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery.
Zhong Y; Zhou Q; Zhang Y; Zhou S; Zhang G; Jiang C; Zhang Z; Zhang X; Xu J; Jin C; Cao L; Chen L
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):135-141. PubMed ID: 32415940
[TBL] [Abstract][Full Text] [Related]
3. Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA.
Pu WY; Zhang R; Xiao L; Wu YY; Gong W; Lv XD; Zhong FY; Zhuang ZX; Bai XM; Li K; Xing CG
BMC Cancer; 2016 Dec; 16(1):943. PubMed ID: 27938352
[TBL] [Abstract][Full Text] [Related]
4. Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery.
Cao G; Xie Y; Jiang X; Tian X; Wang D; Sun Y
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):44-51. PubMed ID: 31472046
[TBL] [Abstract][Full Text] [Related]
5. Quantification of mitochondrial cfDNA reveals new perspectives for early diagnosis of colorectal cancer.
Linke C; Hunger R; Reinwald M; Deckert M; Mantke R
BMC Cancer; 2023 Mar; 23(1):291. PubMed ID: 36997875
[TBL] [Abstract][Full Text] [Related]
6. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
[TBL] [Abstract][Full Text] [Related]
7. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
8. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
Xiao Z; Wu W; Wu C; Li M; Sun F; Zheng L; Liu G; Li X; Yun Z; Tang J; Yu Y; Luo S; Sun W; Feng X; Cheng Q; Tao X; Wu S; Tao J
Mol Oncol; 2021 Jan; 15(1):138-150. PubMed ID: 33107199
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma.
Huang Q; Ji M; Li F; Li Y; Zhou X; Hsueh CY; Zhou L
Mol Cell Probes; 2023 Feb; 67():101895. PubMed ID: 36682577
[TBL] [Abstract][Full Text] [Related]
12. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
14. Multiplexed real-time polymerase chain reaction cell-free DNA assay as a potential method to monitor stage IV colorectal cancer.
Sinha S; Brown H; Tabak J; Fang Z; Tertre MCD; McNamara S; Gambaro K; Batist G; Buell JF
Surgery; 2019 Oct; 166(4):534-539. PubMed ID: 31378479
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
16. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
18. Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology.
Bosque J; Guirao C; Ferrández A; Suarez N; Castillejo MI; Anguita D; Pamies M; Moya A; Soto JL; Gallego Plazas J
Clin Transl Oncol; 2022 Oct; 24(10):1924-1931. PubMed ID: 35499600
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.
Spindler KL; Appelt AL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
Int J Cancer; 2014 Dec; 135(12):2984-91. PubMed ID: 24798213
[TBL] [Abstract][Full Text] [Related]
20. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
